About Amryt Pharma
Amryt Pharma is a company based in Dublin (Ireland) founded in 2015 was acquired by Chiesi Pharmaceuticals in January 2023. Amryt Pharma has completed 4 acquisitions, including Aegerion, Birken and Chiasma. Amryt Pharma offers products and services including Juxtapid / Lojuxta, Myalept / Myalepta, and Mycapssa. Amryt Pharma operates in a competitive market with competitors including Castle Creek Biosciences, QID Pharma, Eicos Sciences and LifeMax, among others.
- Headquarter Dublin, Ireland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amryt Pharma Plc
-
Annual Revenue
$239.89 M (USD)51as on Dec 31, 2015
-
Net Profit
-$73.34 M (USD)-86as on Dec 31, 2015
-
EBITDA
-$45.19 M (USD)-69as on Dec 31, 2015
-
Latest Funding Round
$40 M (USD), Post-IPO
Dec 08, 2020
-
Investors
European Investment Bank
& 7 more
-
Employee Count
Not available
-
Investments & Acquisitions
Aegerion
& 3 more
-
Acquired by
Chiesi Pharmaceuticals
(Jan 08, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amryt Pharma
Amryt Pharma offers a comprehensive portfolio of products and services, including Juxtapid / Lojuxta, Myalept / Myalepta, and Mycapssa.
Treatment for homozygous familial hypercholesterolaemia and related conditions.
Therapy for lipodystrophy and metabolic disorders.
Management for acromegaly and hormonal imbalances.
People of Amryt Pharma
Unlock access to complete
Funding Insights of Amryt Pharma
Investors in Amryt Pharma
Amryt Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Chiesi Pharmaceuticals and Government.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
StonePine Capital Partners is focused on private equity investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Amryt Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amryt Pharma
Amryt Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Aegerion, Birken and Chiasma.
Investment portfolio details for Amryt Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Somatostatin analogue peptides are developed for rare neuroendocrine diseases.
|
Locked | Locked | 2012 | Locked | |
|
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
Locked | Locked | 2005 | Locked | |
|
Therapies for rare diseases are developed via oral platform technology.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Amryt Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Amryt Pharma
Detailed financials for Amryt Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amryt Pharma Comparisons
Peer comparison for Amryt Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amryt Pharma
Amryt Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Castle Creek Biosciences, QID Pharma, Eicos Sciences and LifeMax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene therapy platform for rare disease treatments is developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic dermatology disorders are developed.
|
|
| Locked | Locked | Locked |
Develops Prostacyclin-based therapies for underserved medical conditions globally.
|
|
| Locked | Locked | Locked |
Develops innovative therapeutic solutions for Netherton syndrome treatment.
|
Detailed competitors of Amryt Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amryt Pharma
Complete news archive for Amryt Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amryt Pharma
Amryt Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Amryt Pharma is headquartered in Dublin, Ireland.
Joe Wiley is the current CEO of Amryt Pharma.
Annual revenue of Amryt Pharma is $239.89M as on Dec 31, 2015.
Amryt Pharma was founded in 2015 and is headquartered in Dublin, Ireland. Therapeutics for rare and orphan diseases, particularly in dermatology, are developed by the company. Treatments such as Juxtapid for homozygous familial hypercholesterolemia and Myalepta for lipodystrophy have been created. Products addressing hereditary skin disorders like epidermolysis bullosa are also included in its portfolio. Operations center on pharmaceutical research and development for underserved patient populations.
Amryt Pharma's top competitors include Castle Creek Biosciences, QID Pharma and Eicos Sciences.
Amryt Pharma offers Juxtapid / Lojuxta, Myalept / Myalepta, and Mycapssa.
Amryt Pharma has 8 investors. Key investors include European Investment Bank, Chiesi Pharmaceuticals, Government, Amati Global Investors, and StonePine Capital Partners.